---
title: "Foundayo (orforglipron) in chronic weight management: Storage and supply questions"
description: "Storage and supply questions on Foundayo (orforglipron) in chronic weight management, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: How supplied and Storage. Questions: What strengths do Foundayo tablets come in? What are the NDC numbers for Foundayo? Does Foundayo need to be refrigerated? 3 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/storage-and-supply"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Foundayo (orforglipron) in chronic weight management: Storage and supply questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Foundayo](https://uspl.lilly.com/foundayo/foundayo.html#pi)

## How supplied

<a id="foundayo-strengths"></a>

### What strengths do Foundayo tablets come in?

> “FOUNDAYO tablets are available as orforglipron:
>
> 0.8 mg: pink round tablet debossed with “L” on one side and “G1” on the other side
> 2.5 mg: light yellow round tablet debossed with “L” on one side and “G2” on the other side
> 5.5 mg: grayish purple round tablet debossed with “L” on one side and “G3” on the other side
> 9 mg: pink modified oval tablet debossed with “Lilly” on one side and “G4” on the other side
> 14.5 mg: light yellow modified oval tablet debossed with “Lilly” on one side and “G5” on the other side
> 17.2 mg: grayish purple modified oval tablet debossed with “Lilly” on one side and “G6” on the other side”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=FOUNDAYO%20tablets%20are%20available%20as,%E2%80%9CG6%E2%80%9D%20on%20the%20other%20side)

<a id="foundayo-ndc"></a>

### What are the NDC numbers for Foundayo?

> “FOUNDAYO (orforglipron) tablets are supplied in bottles with desiccant and child-resistant closure in cartons as follows:
>
> Tablet Strength of Orforglipron	Description	Package Configuration	NDC Number
> 0.8 mg	Pink round tablet debossed with “L” on one side and “G1” on the other side	Bottles of 30 tablets	0002-4178-31
> 2.5 mg	Light yellow round tablet debossed with “L” on one side and “G2” on the other side	Bottles of 30 tablets	0002-4503-31
> 5.5 mg	Grayish purple round tablet debossed with “L” on one side and “G3” on the other side	Bottles of 30 tablets	0002-4794-31
> 9 mg	Pink modified oval tablet debossed with “Lilly” on one side and “G4” on the other side	Bottles of 30 tablets	0002-4803-31
> 14.5 mg	Light yellow modified oval tablet debossed with “Lilly” on one side and “G5” on the other side	Bottles of 30 tablets	0002-4839-31
> 17.2 mg	Grayish purple modified oval tablet debossed with “Lilly” on one side and “G6” on the other side	Bottles of 30 tablets	0002-4953-31”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=FOUNDAYO%20%28orforglipron%29%20tablets%20are%20supplied,0002%2D4953%2D31)

## Storage

<a id="foundayo-storage"></a>

### Does Foundayo need to be refrigerated?

> “Store FOUNDAYO at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP Controlled Room Temperature].”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Store%20FOUNDAYO%20at%20room%20temperature,%5BSee%20USP%20Controlled%20Room%20Temperature%5D.)

> “Store at room temperature between 68°F to 77°F (20°C to 25°C).”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Store%20at%20room%20temperature%20between%2068%C2%B0F%20to%2077%C2%B0F%20%2820%C2%B0C%20to%2025%C2%B0C%29.)

## Related pages
- [Medical information: Foundayo (orforglipron): Chronic weight management](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management)
- [Indication](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/safety)
- [Specific populations](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/access-and-coverage)
